Advanced amyloid and tau PET imaging and CSF biomarkers enable in vivo detection of cerebral amyloid and tau pathology and provide critical insights into the underlying disease mechanisms, aiding in the identification of AD pathological changes even at the preclinical or mild cognitive impairment (MCI) stages of AD [8]. Amyloid and Tau PET imaging uses novel radiolabeled tracers that bind selectively to amyloid and tau proteins, allowing for direct visualization and quantification of these pathologic protein deposits, previously only possible through histopathological examination. The gene discussed is MAPT; the disease is Cognitive impairment.